Arcutis Biotherapeutics (ARQT) announced that the first child has been enrolled in a Phase 2 open-label study, INTEGUMENT-INFANT, evaluating the safety and tolerability of investigational ZORYVE cream 0.05% in infants aged 3 months to less than 24 months with atopic dermatitis applied once daily over a four-week period. ZORYVE cream is a highly potent and selective phosphodiesterase-4 inhibitor formulated for topical use.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics presents new long-term results of ZORYVE cream
- Buy Rating for Arcutis Biotherapeutics Driven by FDA Approval and Market Potential of Zoryve Foam
- Arcutis Biotherapeutics: Buy Rating Affirmed on FDA Approval and Promising Commercial Prospects for Zoryve Foam
- Arcutis Biotherapeutics: Buy Rating Affirmed on Strong FDA Approvals and Promising Pipeline
- Arcutis Biotherapeutics reports FDA approves sNDA for Zoryve topical foam
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue